To evaluate the cost-effectiveness of direct oral anticoagulant (DOAC) therapy in patients with device-detected atrial fibrillation (AF) from a health system perspective, particularly considering the uncertainties regarding its clinical benefits.
Approach:
Method: An updated Markov modeling study was conducted to assess the cost-effectiveness of DOAC therapy in patients with subclinical device-detected AF. The analysis measured incremental quality-adjusted life years (QALYs), total costs, and the incremental cost-effectiveness ratio (ICER). The model incorporated specific health states, including stroke, major bleeding, and other relevant outcomes, along with transition probabilities that reflect the progression of the disease and treatment effects.
Key Findings:
The use of anticoagulation therapy was associated with a modest reduction in the risk of stroke; however, it also led to an increased risk of major bleeding complications. The net clinical benefit, as measured by gained QALYs, was found to be minimal and fraught with uncertainty. The study adhered to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines and utilized publicly available data, enhancing the credibility of its findings.
Interpretation:
The findings suggest that while anticoagulation therapy may confer some advantages in terms of stroke prevention, the overall cost-effectiveness remains ambiguous. This uncertainty underscores the importance of careful evaluation and consideration in clinical decision-making regarding anticoagulant use in this patient population.
Limitations:
One significant limitation of the model is the exclusion of nonintracranial bleeding events, which can substantially impact patients' quality of life and overall treatment assessment. Additionally, the analysis was based on a hypothetical patient population, which may not accurately reflect the complexities and variations present in real-world clinical settings. This limitation calls for caution when attempting to generalize the results to broader patient populations.
Conclusion:
The cost-effectiveness of DOAC therapy in patients with subclinical AF has not been definitively established, despite the potential for marginal clinical benefits. This highlights the necessity for further research to clarify the role of anticoagulants in this context and to inform clinical guidelines.
